Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2929-2932

  Arun Muthuve, Veluswamy ^a   Jaya, Vijayaraghavan ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

CA125; Malignancy; Ovarian tumours; Rmi; Staging; Ultrasound

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADULT; BLOOD; CANCER STAGING; DECISION SUPPORT SYSTEM; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; FEMALE; FOLLOW UP; HEALTH STATUS INDICATOR; HUMAN; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; YOUNG ADULT;

ADULT; CA-125 ANTIGEN; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899849623     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2929     Document Type: Article

References (19)

1. Bast RC, Badgwell D, Lu Z, et al. (2005). New tumor markers: CA125 and beyond. Int J Gynecol Cancer, 3 274-81.
2. Bruchim I, Ben-harim Z, Piura E, Tepper R, Fishman A. (2013). Preoperative clinical and radiological features of metastatic ovarian tumors. Arch Gynecol Obstet, 288, 615-9.
3. Dodge JE, Covens AL, Lacchetti C, et al. (2012). Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol, 126, 157-66.
4. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. (2009). The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol, 113, 384-94.
5. Jacob F, Meier M, Caduff R, et al. (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol, 121, 487-91.
6. Jacobs I, Oram D, Fairbanks J, et al. (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol, 97, 922-9.
7. Jelovac D, Armstrong DK(2011). Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin, 61, 183-203.
8. Bian J, Li B, Kou XJ, Liu T-Z, Ming L. (2013). Clinical Significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev, 14, 6241-3
9. Kawai M, Kano T, Kikkawa F, et al. (1992). Transvaginal doppler ultrasound with color flow imaging in the diagnosis of ovarian cancer. Obstet Gynecol, 79, 163-7.
10. Li L, Xu Y, Yu C-X. (2013). Proteomic analysis of serum of women with elevated ca-125 to differentiate malignant from benign ovarian tumors. Asian Pac J Cancer Prev, 13, 3265-70
11. Menon U, Gentry-Maharaj A, Hallett R, et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative Trial of ovarian cancer screening. (UKCTOCS). The Lancet Oncology, 10, 327-40.
12. Rafii A, Halabi NM, Malek JA. (2012). High-prevalence and broad spectrum of cell adhesion and extracellular matrix gene pathway mutations in epithelial ovarian cancer. J Clin Bioinforma, 2, 15.
13. Stashwick C, Post MD, Arruda JS, et al. (2011). Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer, 21, 1422-7.
14. Tingulstad S, Hagen B, Skjeldestad FE, et al. (1996). Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol, 103, 826-31.
15. Tingulstad S, Hagen B, Skjeldestad FE, et al. (1999). The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol, 93, 448-52.
16. Van trappen PO, Rufford BD, Mills TD, et al. (2007). Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer, 17, 61-7.
17. Vergote I, Trope CG, Amant F, et al. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med, 363, 943-53.
18. Webb PM, Purdie DM, Grover S, et al. (2004). Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol, 92, 232-9.
19. Yurkovetsky Z, Skates S, Lomakin A, et al. (2010). Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol, 28, 2159-66.